Phew....I think we dodged a bullet. This latest work in Nature suggests a longer dosing. In the phase 2 for heart on file with the FDA (delayed now)....RGN was dosing once a day for three days, then once weekly a handful of weeks after. One of the docs in teh article ugest a longer dosing of more than 3 days.
Trial design (and execution) has always been a BAD spot for RGN. Maybe we got lucky on this delay: